Communiqués Bayer AG Warsaw S.E.

Actions

BAY

DE000BAY0017

Marché Fermé - Warsaw S.E. Autres places de cotation 17:55:46 16/07/2024			Varia. 5j.	Varia. 1 janv.
110,2 ^PLN	-3,01%		-3,96%	-25,79%

16/07	ORIC Pharmaceuticals, Inc. conclut des accords de collaboration et de fourniture d'essais cliniques avec Bayer et Janssen Research & Development, LLC	CI
15/07	BAYER AG : UBS est neutre	ZD

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Bayer AG - AskBio receives FDA Fast Track and MHRA Innovation Passport designations for AB-1005 investigational GDNF gene therapy for Parkinson's disease	12/07	AQ
Bayer Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	26/06	EQ
Bayer Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	20/06	EQ
Bayer Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	23/05	EQ
Bayer Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	22/05	EQ
Bayer Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	21/05	EQ
Bayer : Q1 Media Update	14/05	PU
Bayer : First-quarter performance as expected	14/05	PU
Bayer : Debt Investor Information FY 2023 / Q1 2024 (DE)	14/05	PU
Bayer : Debt Investor Information FY 2023 Q1 204	14/05	PU
Bayer : Quarterly Statement First Quarter 2024	14/05	PU
Bayer : Address by Bill Anderson	26/04	PU
Bayer : Address by Bill Anderson	22/04	PU
Bayer : Explanations to the Supervisory Board Report - Prof. Dr. Norbert Winkeljohann	22/04	PU
Bayer Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	17/04	EQ
Bayer - AskBio Names Mansuo Shannon Chief Scientific Officer	10/04	AQ
Bayer and Vividion Therapeutics to highlight advancing oncology portfolio at AACR 2024 Annual Meeting	04/04	AQ
Bayer Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	03/04	EQ
Bayer Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	27/03	EQ
Bayer Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	22/03	EQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

A la une

BAYER : Aussi doux que prévu

Le 14 mai 2024 à 20:12

Bayer AG : Pas au bout de ses peines

Le 06 mars 2024 à 13:58